Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study

被引：0

作者：

Min Zheng

Xiang Chen

Feng Wang

Jisu Chen

Kimberley Jackson

Fan Yang

Christopher Payne

HongYing Li

YiHui Wang

ZiPei Xiao

Jie Zheng

机构：

[1] The Second Affiliated Hospital,Department of Dermatology

[2] Zhejiang University School of Medicine,Department of Dermatology

[3] Xiangya Hospital,Department of Dermatology, School of Medicine

[4] Central South University,undefined

[5] Lilly Suzhou Pharmaceutical Co. Ltd,undefined

[6] Eli Lilly and Company,undefined

[7] Eli Lilly and Company,undefined

[8] Rui Jin Hospital,undefined

[9] Shanghai Jiao Tong University,undefined

来源：

Advances in Therapy | 2023年 / 40卷

关键词：

Psoriasis; Interleukin-17A; Phase 1; Pharmacokinetics; Safety;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：3804 / 3816

页数：12

共 50 条

[21] Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)
Imafuku, Shinichi
Torisu-Itakura, Hitoe
Nishikawa, Atsushi
Zhao, Fangyi
Cameron, Gregory S.
[J]. JOURNAL OF DERMATOLOGY, 2017, 44 (11): : 1285 - 1290
[22] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
Leonardi, C.
Leutz, A.
Blauvelt, A.
Langley, R. G.
Luger, T.
Ohtsuki, M.
Cameron, G. S.
Erickson, J.
Zhao, F.
Shrom, D. S.
Braun, D.
Osuntokun, O. O.
Heffernan, M.
Nickoloff, B. J.
Gordon, K.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
[23] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
Leonardi, Craig
Blauvelt, Andrew
Langley, Richard
Luger, Thomas
Ohtsuki, Mamitaro
Cameron, Gregory S.
Braun, Daniel
Erickson, Janelle
Zhao, Fangyi
Shrorn, David S.
Osuntokun, Olawale O.
Heffernan, Michael P.
Nickoloff, Brian
Gordon, Kenneth
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
[24] Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
Cui, Yimin
Song, Yan
Wang, Jessie
Yu, Zhigang
Schuster, Alan
Barrett, Yu Chen
Frost, Charles
[J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 177 - 184
[25] Early onset of clinical improvement with ixekizumab in patients with moderate-to-severe plaque psoriasis
Khatri, S.
Amir, Y.
Min, M.
Goldblum, O.
Solotkin, K.
Yang, F.
Ridenour, T.
Lebwohl, M.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 73 - 74
[26] Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects
Hu, Chaoying
Wang, Yijun
Song, Rong
Yu, Chen
Luo, Xiaoyan
Jia, Jingying
[J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (09) : 861 - 871
[27] Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects
Chaoying Hu
Yijun Wang
Rong Song
Chen Yu
Xiaoyan Luo
Jingying Jia
[J]. Clinical Drug Investigation, 2017, 37 : 861 - 871
[28] Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment
Barth, Juergen
Jaeger, Doris
Mundkowski, Ralf
Drewelow, Bernd
Welte, Tobias
Burkhardt, Olaf
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (03) : 575 - 578
[29] Single- and Multiple-Dose Pharmacokinetics of Tofacitinib in Healthy Chinese Volunteers
Krishnaswami, Sriram
Wang, Tao
Yuan, Yi
Alvey, Christine W.
Checchio, Tina
Peterson, Mark
Shi, Haihong
Riese, Richard
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (05): : 395 - 399
[30] Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects
Sun, De-qing
Wang, Hai-sheng
Ni, Mei-yuan
Wang, Ben-jie
Guo, Rui-chen
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (01) : 15 - 23

← 1 2 3 4 5 →